TOUJEO Max is a Subcutaneous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Sanofi-aventis U.s. Llc. The primary component is Insulin Glargine.
| Product ID | 0024-5871_032d4bb7-48bd-4751-9366-9ec46b7ff010 |
| NDC | 0024-5871 |
| Product Type | Human Prescription Drug |
| Proprietary Name | TOUJEO Max |
| Generic Name | Insulin Glargine |
| Dosage Form | Injection, Solution |
| Route of Administration | SUBCUTANEOUS |
| Marketing Start Date | 2015-02-15 |
| Marketing Category | NDA / NDA |
| Application Number | NDA206538 |
| Labeler Name | Sanofi-Aventis U.S. LLC |
| Substance Name | INSULIN GLARGINE |
| Active Ingredient Strength | 300 U/mL |
| Pharm Classes | Insulin [Chemical/Ingredient],Insulin Analog [EPC] |
| NDC Exclude Flag | N |
| Listing Certified Through | 2020-12-31 |
| Marketing Start Date | 2018-03-26 |
| NDC Exclude Flag | N |
| Sample Package? | Y |
| Marketing Category | BLA |
| Application Number | BLA206538 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | ML |
| Marketing Start Date | 2015-02-15 |
| Marketing Category | BLA |
| Application Number | BLA206538 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | ML |
| Marketing Start Date | 2018-03-26 |
| Marketing Category | BLA |
| Application Number | BLA206538 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | ML |
| Marketing Start Date | 2018-03-26 |
| Ingredient | Strength |
|---|---|
| INSULIN GLARGINE | 300 U/mL |
| SPL SET ID: | c9561d96-124d-48ca-982f-0aa1575bff36 |
| Manufacturer | |
| UNII | |
| RxNorm Concept Unique ID - RxCUI | |
| PHarm Class EPC | |
| NUI Code |
| NDC | Brand Name | Generic Name |
|---|---|---|
| 0024-5871 | TOUJEO Max | insulin glargine |
| 50090-4177 | TOUJEO Max | TOUJEO Max |
| 0002-7715 | BASAGLAR | Insulin glargine |
| 0002-8214 | BASAGLAR | Insulin glargine |
| 0088-2220 | Lantus | insulin glargine |
| 0088-2219 | Lantus Solostar | insulin glargine |
| 0024-5869 | TOUJEO | insulin glargine |